JP2021508686A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021508686A5 JP2021508686A5 JP2020533840A JP2020533840A JP2021508686A5 JP 2021508686 A5 JP2021508686 A5 JP 2021508686A5 JP 2020533840 A JP2020533840 A JP 2020533840A JP 2020533840 A JP2020533840 A JP 2020533840A JP 2021508686 A5 JP2021508686 A5 JP 2021508686A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- haloalkyl
- alkoxy
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 36
- 125000003545 alkoxy group Chemical group 0.000 claims 22
- 125000001188 haloalkyl group Chemical group 0.000 claims 21
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 17
- 125000004103 aminoalkyl group Chemical group 0.000 claims 17
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims 17
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 17
- 125000004438 haloalkoxy group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000003282 alkyl amino group Chemical group 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 125000002947 alkylene group Chemical group 0.000 claims 8
- -1 cyano, hydroxyl Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 230000004761 fibrosis Effects 0.000 claims 5
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 claims 2
- 101710149745 Lysophosphatidic acid receptor 1 Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 206010072877 Intestinal fibrosis Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000002850 nasal mucosa Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 0 *C*c1c(*)nn[n]1* Chemical compound *C*c1c(*)nn[n]1* 0.000 description 7
- WSBKVCOOKFNBER-OALUTQOASA-N C[n]1nnc(-c(cc2)nc(COC)c2O[C@@H](CCC2)C[C@H]2C(O)=O)c1CNC(OCc1ccccc1)=O Chemical compound C[n]1nnc(-c(cc2)nc(COC)c2O[C@@H](CCC2)C[C@H]2C(O)=O)c1CNC(OCc1ccccc1)=O WSBKVCOOKFNBER-OALUTQOASA-N 0.000 description 1
- UBISPEKHXDFDPN-ROUUACIJSA-N Cc1nc(-c2c(CNC(OCc3ccccc3)=O)[n](C)nn2)cnc1O[C@@H](CCC1)C[C@H]1C(O)=O Chemical compound Cc1nc(-c2c(CNC(OCc3ccccc3)=O)[n](C)nn2)cnc1O[C@@H](CCC1)C[C@H]1C(O)=O UBISPEKHXDFDPN-ROUUACIJSA-N 0.000 description 1
- IGHOUELBDVQBNR-XJDOXCRVSA-N Cc1nc(-c2c(CNS(N(C)Cc3ccccc3)(=O)=O)[n](C)nn2)ccc1OC(CCC1)C[C@H]1C(O)=O Chemical compound Cc1nc(-c2c(CNS(N(C)Cc3ccccc3)(=O)=O)[n](C)nn2)ccc1OC(CCC1)C[C@H]1C(O)=O IGHOUELBDVQBNR-XJDOXCRVSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607399P | 2017-12-19 | 2017-12-19 | |
| US62/607,399 | 2017-12-19 | ||
| PCT/US2018/066117 WO2019126090A1 (en) | 2017-12-19 | 2018-12-18 | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021508686A JP2021508686A (ja) | 2021-03-11 |
| JP2021508686A5 true JP2021508686A5 (enExample) | 2021-12-16 |
| JP7274486B2 JP7274486B2 (ja) | 2023-05-16 |
| JP7274486B6 JP7274486B6 (ja) | 2024-02-15 |
Family
ID=65003579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020533840A Active JP7274486B6 (ja) | 2017-12-19 | 2018-12-18 | Ｌｐａアンタゴニストとしてのトリアゾールｎ結合カルバモイルシクロヘキシル酸 |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US10662172B2 (enExample) |
| EP (2) | EP3710438B1 (enExample) |
| JP (1) | JP7274486B6 (enExample) |
| KR (1) | KR102702229B1 (enExample) |
| CN (2) | CN112521368B (enExample) |
| AR (1) | AR113964A1 (enExample) |
| AU (1) | AU2018392321B2 (enExample) |
| CA (1) | CA3085586C (enExample) |
| CL (1) | CL2020001547A1 (enExample) |
| CY (1) | CY1124863T1 (enExample) |
| DK (1) | DK3710438T3 (enExample) |
| EA (1) | EA202091506A1 (enExample) |
| ES (1) | ES2898364T3 (enExample) |
| HR (1) | HRP20211918T8 (enExample) |
| HU (1) | HUE057366T2 (enExample) |
| IL (1) | IL275348B2 (enExample) |
| LT (1) | LT3710438T (enExample) |
| MX (1) | MX394467B (enExample) |
| MY (1) | MY199103A (enExample) |
| NZ (1) | NZ766284A (enExample) |
| PE (1) | PE20210655A1 (enExample) |
| PL (1) | PL3710438T3 (enExample) |
| PT (1) | PT3710438T (enExample) |
| RS (1) | RS62710B1 (enExample) |
| SG (1) | SG11202005699QA (enExample) |
| SI (1) | SI3710438T1 (enExample) |
| SM (1) | SMT202100716T1 (enExample) |
| TW (1) | TWI830713B (enExample) |
| WO (1) | WO2019126090A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| WO2019126084A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| EP3728222B1 (en) | 2017-12-19 | 2023-03-29 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as lpa antagonists |
| US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
| WO2019126094A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azoles as lpa antagonists |
| EA202091500A1 (ru) | 2017-12-19 | 2020-09-14 | Бристол-Маерс Сквибб Компани | Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa |
| WO2019126087A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as lpa antagonists |
| AR113964A1 (es) | 2017-12-19 | 2020-07-01 | Bristol Myers Squibb Co | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa |
| WO2019126086A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
| CA3085561A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azines as lpa antagonists |
| KR102726939B1 (ko) | 2017-12-19 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 피라졸 아졸 |
| CN112041302B (zh) | 2017-12-19 | 2024-11-19 | 百时美施贵宝公司 | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 |
| HUE060711T2 (hu) | 2017-12-19 | 2023-04-28 | Turning Point Therapeutics Inc | Makrociklusos vegyületek betegségek kezelésére |
| US12428430B2 (en) | 2018-09-18 | 2025-09-30 | Bristol-Myers Squibb Company | Oxabicyclo acids as LPA antagonists |
| KR20210061383A (ko) | 2018-09-18 | 2021-05-27 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로펜틸 산 |
| JP7367038B2 (ja) * | 2018-10-15 | 2023-10-23 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａ１受容体のイメージングのための放射性リガンド |
| CN111434653A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 三氮唑类化合物及其制备方法与用途 |
| KR20220039718A (ko) | 2019-07-30 | 2022-03-29 | 다이쇼 세이야꾸 가부시끼가이샤 | Lpa1 수용체를 길항하는 우레아 화합물 |
| CN110590599B (zh) * | 2019-09-30 | 2022-07-26 | 大连民族大学 | 一种群体感应信号分子结构类似物及其制备方法 |
| CN114728168B (zh) | 2019-11-15 | 2024-04-09 | 吉利德科学公司 | 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 |
| CN114786771A (zh) | 2019-12-12 | 2022-07-22 | 奇斯药制品公司 | 作为lpa受体2抑制剂的喹唑啉衍生物 |
| EP4073069B1 (en) | 2019-12-12 | 2023-12-06 | Chiesi Farmaceutici S.p.A. | Aromatic amido derivatives as lpa receptor 2 inhibitors |
| EP4073073B1 (en) | 2019-12-12 | 2023-12-06 | Chiesi Farmaceutici S.p.A. | Thienopyrimidine derivatives as lpa receptor 2 inhibitors |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| EP4161936A1 (en) | 2020-06-03 | 2023-04-12 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| CN115989220A (zh) | 2020-07-16 | 2023-04-18 | 奇斯药制品公司 | 作为lpa受体抑制剂的酰氨基环己烷酸衍生物 |
| CN114456159A (zh) * | 2020-11-10 | 2022-05-10 | 武汉人福创新药物研发中心有限公司 | 氮取代杂环噻吩类化合物及其用途 |
| WO2022115049A1 (en) | 2020-11-25 | 2022-06-02 | Yeditepe Universitesi | Molecular basis of fatty liver inhibition by sodium borates |
| WO2022174883A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| WO2022174882A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| WO2022199815A1 (en) | 2021-03-24 | 2022-09-29 | Chiesi Farmaceutici S.P.A. | 8-cyclo-substituted quinazoline derivatives as lpa receptor 2 inhibitors |
| EP4337641A1 (en) | 2021-05-11 | 2024-03-20 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| JP7691522B2 (ja) * | 2021-05-13 | 2025-06-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| EP4444707A1 (en) | 2021-12-08 | 2024-10-16 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2023118253A1 (en) | 2021-12-23 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Cyclohexane acid derivatives as lpa receptor inhibitors |
| US20250188068A1 (en) | 2022-03-08 | 2025-06-12 | Chiesi Farmaceutici S.P.A. | Amido cyclopropyl derivatives as lpa receptor inhibitors |
| WO2025051267A1 (zh) * | 2023-09-08 | 2025-03-13 | 西藏海思科制药有限公司 | 一种lpar1拮抗剂及其用途 |
| WO2025051266A1 (zh) * | 2023-09-08 | 2025-03-13 | 西藏海思科制药有限公司 | 杂芳环衍生物的lpar1拮抗剂及其用途 |
| WO2025162421A1 (zh) * | 2024-02-04 | 2025-08-07 | 西藏海思科制药有限公司 | Lpar1拮抗剂及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001060819A1 (en) | 2000-02-18 | 2001-08-23 | Kirin Beer Kabushiki Kaisha | Novel isoxazole and thiazole compounds and use thereof as drugs |
| DE60234318D1 (de) | 2001-02-08 | 2009-12-24 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
| WO2005012269A1 (ja) | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | 新規アゾール化合物 |
| US7432271B2 (en) | 2003-09-02 | 2008-10-07 | Bristol-Myers Squibb Company | Pyrazolyl inhibitors of 15-lipoxygenase |
| DE102004038403B4 (de) | 2004-08-07 | 2006-08-31 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| GB0806794D0 (en) | 2008-04-15 | 2008-05-14 | Ludwig Inst Cancer Res | Therapeutic compounds |
| EP2462128B1 (en) | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| US8742097B2 (en) | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| CN103443098B (zh) | 2011-01-30 | 2016-03-16 | 广州源生医药科技有限公司 | 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用 |
| JP5976011B2 (ja) | 2011-04-05 | 2016-08-23 | 武田薬品工業株式会社 | スルホンアミド誘導体およびその用途 |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| WO2013070879A1 (en) | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| WO2013085824A1 (en) | 2011-12-04 | 2013-06-13 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| MA37764A1 (fr) | 2012-06-20 | 2016-01-29 | Hoffmann La Roche | Composés n-alkyltriazole utilisés comme antagonistes de lpar |
| TW201437200A (zh) * | 2013-01-15 | 2014-10-01 | Intermune Inc | 溶血磷脂酸受體拮抗劑 |
| CN105142635B (zh) | 2013-03-15 | 2021-07-27 | 艾匹根生物技术有限公司 | 有用于治疗疾病的杂环化合物 |
| WO2016044556A2 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| JP6853619B2 (ja) * | 2015-01-16 | 2021-03-31 | 大塚製薬株式会社 | シアノトリアゾール化合物の医薬用途 |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| WO2019126086A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
| WO2019126087A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as lpa antagonists |
| HUE060711T2 (hu) | 2017-12-19 | 2023-04-28 | Turning Point Therapeutics Inc | Makrociklusos vegyületek betegségek kezelésére |
| CA3085561A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azines as lpa antagonists |
| KR102726939B1 (ko) | 2017-12-19 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 피라졸 아졸 |
| WO2019126084A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| CN112041302B (zh) | 2017-12-19 | 2024-11-19 | 百时美施贵宝公司 | 作为lpa拮抗剂的吡唑o-连接的氨基甲酰基环己基酸 |
| AR113964A1 (es) | 2017-12-19 | 2020-07-01 | Bristol Myers Squibb Co | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa |
| US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
| WO2019126094A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azoles as lpa antagonists |
| EP3728222B1 (en) | 2017-12-19 | 2023-03-29 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as lpa antagonists |
| EA202091500A1 (ru) | 2017-12-19 | 2020-09-14 | Бристол-Маерс Сквибб Компани | Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa |
-
2018
- 2018-12-18 AR ARP180103700A patent/AR113964A1/es unknown
- 2018-12-18 DK DK18830680.7T patent/DK3710438T3/da active
- 2018-12-18 SI SI201830475T patent/SI3710438T1/sl unknown
- 2018-12-18 CN CN202011353094.2A patent/CN112521368B/zh active Active
- 2018-12-18 EP EP18830680.7A patent/EP3710438B1/en active Active
- 2018-12-18 JP JP2020533840A patent/JP7274486B6/ja active Active
- 2018-12-18 RS RS20211542A patent/RS62710B1/sr unknown
- 2018-12-18 PT PT188306807T patent/PT3710438T/pt unknown
- 2018-12-18 KR KR1020207020553A patent/KR102702229B1/ko active Active
- 2018-12-18 CN CN201880080910.1A patent/CN112189010A/zh active Pending
- 2018-12-18 ES ES18830680T patent/ES2898364T3/es active Active
- 2018-12-18 PE PE2020000746A patent/PE20210655A1/es unknown
- 2018-12-18 EA EA202091506A patent/EA202091506A1/ru unknown
- 2018-12-18 MX MX2020006315A patent/MX394467B/es unknown
- 2018-12-18 HR HRP20211918TT patent/HRP20211918T8/hr unknown
- 2018-12-18 CA CA3085586A patent/CA3085586C/en active Active
- 2018-12-18 TW TW107145551A patent/TWI830713B/zh not_active IP Right Cessation
- 2018-12-18 NZ NZ766284A patent/NZ766284A/en not_active IP Right Cessation
- 2018-12-18 HU HUE18830680A patent/HUE057366T2/hu unknown
- 2018-12-18 MY MYPI2020003100A patent/MY199103A/en unknown
- 2018-12-18 WO PCT/US2018/066117 patent/WO2019126090A1/en not_active Ceased
- 2018-12-18 SG SG11202005699QA patent/SG11202005699QA/en unknown
- 2018-12-18 EP EP21203235.3A patent/EP4011875A1/en not_active Withdrawn
- 2018-12-18 US US16/223,169 patent/US10662172B2/en active Active
- 2018-12-18 PL PL18830680T patent/PL3710438T3/pl unknown
- 2018-12-18 LT LTEPPCT/US2018/066117T patent/LT3710438T/lt unknown
- 2018-12-18 SM SM20210716T patent/SMT202100716T1/it unknown
- 2018-12-18 AU AU2018392321A patent/AU2018392321B2/en active Active
-
2020
- 2020-01-16 US US16/744,303 patent/US11008300B2/en active Active
- 2020-06-10 CL CL2020001547A patent/CL2020001547A1/es unknown
- 2020-06-14 IL IL275348A patent/IL275348B2/en unknown
-
2021
- 2021-04-07 US US17/224,161 patent/US11697646B2/en active Active
- 2021-12-14 CY CY20211101119T patent/CY1124863T1/el unknown
-
2023
- 2023-05-22 US US18/321,092 patent/US12195444B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021508686A5 (enExample) | ||
| HRP20211918T1 (hr) | Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti | |
| JP2021507900A5 (enExample) | ||
| JPWO2019126086A5 (enExample) | ||
| JPWO2019126099A5 (enExample) | ||
| JP2020537657A5 (enExample) | ||
| JP2019094345A5 (enExample) | ||
| JPWO2020060915A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| JP2014513704A5 (enExample) | ||
| JPWO2019126085A5 (enExample) | ||
| JP2010539110A5 (enExample) | ||
| JP2018515438A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2016535784A5 (enExample) | ||
| JP2013509431A5 (enExample) | ||
| JP2021502358A5 (enExample) | ||
| RU2012103487A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| JPWO2021081212A5 (enExample) | ||
| RU2012151012A (ru) | Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием | |
| JP6966425B2 (ja) | 抗がん剤としての複素環式の限定された三環系スルホンアミド | |
| JP2009521483A5 (enExample) | ||
| JP2018516963A5 (enExample) | ||
| JP2020504716A5 (enExample) | ||
| JP2015531764A5 (enExample) |